10-K: Journey Medical Corporation Reports 2023 Financial Results and Provides Business Update

Journey Medical Corporation's 2023 annual report details financial performance, strategic initiatives, and regulatory progress, including a new credit facility and a license agreement.

Summary

• Journey Medical Corporation, a commercial-stage pharmaceutical company focused on dermatology, released its 2023 annual report.
• The company's revenue totaled $79.2 million, a 7% increase from the previous year, driven by a $19 million upfront payment from Maruho for licensing rights.
• Net product revenue decreased by 16% to $59.7 million due to generic competition and higher rebates.
• Operating expenses decreased by 20% to $81.3 million, reflecting cost reduction efforts.
• The company reported a net loss of $3.9 million, a significant improvement from the $29.6 million loss in 2022.
• Journey Medical secured a $20 million credit facility with SWK Funding, drawing $15 million initially.
• The company submitted a New Drug Application (NDA) for DFD-29, a rosacea treatment, with potential FDA approval expected in the second half of 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments like the new credit facility and progress on DFD-29, the company faces significant challenges, including declining product revenue, generic competition, and concerns about its ability to continue as a going concern. The sentiment is therefore neutral to slightly negative.

Positives

• The company secured a $20 million credit facility, providing additional financial flexibility.
• The company received a $19 million upfront payment from Maruho, boosting revenue.
• The company made progress on DFD-29, submitting an NDA with potential FDA approval in the second half of 2024.
• The company reduced operating expenses by 20%, improving profitability.
• The company's net loss improved significantly from $29.6 million in 2022 to $3.9 million in 2023.

Negatives

• Net product revenue decreased by 16% due to generic competition and higher rebates.
• The company discontinued selling Ximino in September 2023.
• The company incurred a $3.1 million loss on impairment of intangible assets related to Ximino.
• The company has a history of net losses and expresses substantial doubt about its ability to continue as a going concern.

Risks

• The company's products are subject to time and cost-intensive regulation and clinical testing.
• A substantial portion of sales derive from products without patent protection, facing generic competition.
• The company relies on third parties for manufacturing and clinical trials, which could cause delays.
• The company may need to raise additional capital, which may not be available on acceptable terms.
• Fortress Biotech controls a voting majority of the company's stock, which could be detrimental to other shareholders.
• There is substantial doubt regarding the company's ability to continue as a going concern.

Future Outlook

The company expects potential FDA approval for DFD-29 in the second half of 2024 and plans to launch an anti-itch product through its field sales force during the second half of 2024 or first half of 2025.

Management Comments

• The company aims to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, these products through our field sales organization.
• The company believes that consolidation in the medical dermatology industry has resulted in an enhanced opportunity for a medical dermatology-focused company to build relationships with these stakeholders and has made available a large and growing talent pool of experienced individuals who can make significant contributions to our Company.

Industry Context

The dermatology market is highly competitive, with many mid-size and smaller companies competing in both the prescription and OTC sectors. Journey Medical faces competition from manufacturers of generic pharmaceutical products and must demonstrate that its products offer medical and cost advantages compared to other forms of care.

Comparison to Industry Standards

• The company's reliance on third-party manufacturers is common in the pharmaceutical industry, but it introduces risks related to supply and compliance.
• The company's focus on dermatology is a strategic move in a fragmented market, but it faces competition from larger companies with greater resources.
• The company's use of the 505(b)(2) regulatory pathway for DFD-29 is a common strategy to expedite drug approval, but it carries risks related to patent litigation and regulatory delays.
• The company's financial performance is mixed, with revenue growth offset by increased competition and higher rebates, which is a common challenge for pharmaceutical companies.

Related Party Transactions

• The company has a shared services agreement with Fortress Biotech, Inc., its majority owner, for management and administrative services.

Stakeholder Impact

• Shareholders face risks due to the company's financial challenges and Fortress Biotech's control.
• Employees may be affected by cost reduction initiatives and potential restructuring.
• Customers may benefit from new products and treatments, but could be impacted by supply chain issues.
• Suppliers and creditors face risks due to the company's financial instability.

Next Steps

• The company expects potential FDA approval for DFD-29 in the second half of 2024.
• The company plans to launch an anti-itch product through its field sales force during the second half of 2024 or first half of 2025.
• The company will continue to evaluate business development opportunities, including acquisitions and licensing.

Key Dates

Keywords

dermatology, pharmaceutical, rosacea, acne, hyperhidrosis, DFD-29, Qbrexza, Amzeeq, Zilxi, Accutane, FDA, clinical trials, licensing, credit facility, generic competition